Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jean J. Zhao, Ph.D.

Co-Author

This page shows the publications co-authored by Jean Zhao and Thomas Roberts.
Connection Strength

6.171
  1. PI3 kinases in cancer: from oncogene artifact to leading cancer target. Sci STKE. 2006 Dec 12; 2006(365):pe52.
    View in: PubMed
    Score: 0.345
  2. The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc Natl Acad Sci U S A. 2006 Oct 31; 103(44):16296-300.
    View in: PubMed
    Score: 0.341
  3. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A. 2005 Dec 20; 102(51):18443-8.
    View in: PubMed
    Score: 0.321
  4. Blocking PI3K p110ß Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer. Mol Cancer Res. 2022 Feb 01.
    View in: PubMed
    Score: 0.246
  5. The role of the PIK3CA gene in the development and aging of the brain. Sci Rep. 2021 01 11; 11(1):291.
    View in: PubMed
    Score: 0.229
  6. Divergent Roles of PI3K Isoforms in PTEN-Deficient Glioblastomas. Cell Rep. 2020 09 29; 32(13):108196.
    View in: PubMed
    Score: 0.224
  7. PIK3CA C-terminal frameshift mutations are novel oncogenic events that sensitize tumors to PI3K-a inhibition. Proc Natl Acad Sci U S A. 2020 09 29; 117(39):24427-24433.
    View in: PubMed
    Score: 0.224
  8. PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. Cell Rep. 2018 12 11; 25(11):2972-2980.e5.
    View in: PubMed
    Score: 0.198
  9. Targeted Profiling of RNA Translation. Curr Protoc Mol Biol. 2019 01; 125(1):e71.
    View in: PubMed
    Score: 0.196
  10. A Conditional Dependency on MELK for the Proliferation of Triple-Negative Breast Cancer Cells. iScience. 2018 Nov 30; 9:149-160.
    View in: PubMed
    Score: 0.196
  11. Targeted profiling of RNA translation reveals mTOR-4EBP1/2-independent translation regulation of mRNAs encoding ribosomal proteins. Proc Natl Acad Sci U S A. 2018 10 02; 115(40):E9325-E9332.
    View in: PubMed
    Score: 0.195
  12. Isoform-Selective Phosphatidylinositol 3-Kinase Inhibition in Cancer. J Clin Oncol. 2018 05 01; 36(13):1339-1342.
    View in: PubMed
    Score: 0.188
  13. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017 08 24; 548(7668):471-475.
    View in: PubMed
    Score: 0.181
  14. CRKL Mediates p110ß-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells. Cell Rep. 2017 07 18; 20(3):549-557.
    View in: PubMed
    Score: 0.180
  15. PI3K-p110a mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85a. Proc Natl Acad Sci U S A. 2017 07 03; 114(27):7095-7100.
    View in: PubMed
    Score: 0.179
  16. The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer. Biochim Biophys Acta Rev Cancer. 2017 Aug; 1868(1):123-131.
    View in: PubMed
    Score: 0.175
  17. Rac1-mediated membrane raft localization of PI3K/p110ß is required for its activation by GPCRs or PTEN loss. Elife. 2016 10 04; 5.
    View in: PubMed
    Score: 0.170
  18. NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K-AKT and JAK-STAT3 pathways. Cell Discov. 2016; 2:16030.
    View in: PubMed
    Score: 0.170
  19. Tyrosine receptor kinase B is a drug target in astrocytomas. Neuro Oncol. 2017 01; 19(1):22-30.
    View in: PubMed
    Score: 0.167
  20. Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nat Med. 2016 07; 22(7):723-6.
    View in: PubMed
    Score: 0.166
  21. Corrigendum: Essential roles of PI(3)K-p110ß in cell growth, metabolism and tumorigenesis. Nature. 2016 05 12; 533(7602):278.
    View in: PubMed
    Score: 0.162
  22. A PI3K p110ß-Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis. Nat Commun. 2015 Oct 07; 6:8501.
    View in: PubMed
    Score: 0.159
  23. PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context. Proc Natl Acad Sci U S A. 2014 Apr 29; 111(17):6395-400.
    View in: PubMed
    Score: 0.143
  24. Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110a. J Clin Invest. 2014 Apr; 124(4):1794-809.
    View in: PubMed
    Score: 0.142
  25. Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. Cancer Discov. 2013 Jan; 3(1):44-51.
    View in: PubMed
    Score: 0.131
  26. The p110a and p110ß isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. Genes Dev. 2012 Jul 15; 26(14):1573-86.
    View in: PubMed
    Score: 0.127
  27. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug; 8(8):627-44.
    View in: PubMed
    Score: 0.103
  28. Should individual PI3 kinase isoforms be targeted in cancer? Curr Opin Cell Biol. 2009 Apr; 21(2):199-208.
    View in: PubMed
    Score: 0.100
  29. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature. 2008 Aug 07; 454(7205):776-9.
    View in: PubMed
    Score: 0.096
  30. Surveillance mechanism linking Bub1 loss to the p53 pathway. Proc Natl Acad Sci U S A. 2007 May 15; 104(20):8334-9.
    View in: PubMed
    Score: 0.089
  31. The p110alpha isoform of phosphatidylinositol 3-kinase is essential for polyomavirus middle T antigen-mediated transformation. J Virol. 2007 Jul; 81(13):7069-76.
    View in: PubMed
    Score: 0.088
  32. Functional genetics and experimental models of human cancer. Trends Mol Med. 2004 Jul; 10(7):344-50.
    View in: PubMed
    Score: 0.073
  33. Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. Cancer Cell. 2003 May; 3(5):483-95.
    View in: PubMed
    Score: 0.067
  34. Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers. Oncogene. 2020 01; 39(1):50-63.
    View in: PubMed
    Score: 0.052
  35. PI3 kinase alpha and delta promote hematopoietic stem cell activation. JCI Insight. 2019 05 23; 5.
    View in: PubMed
    Score: 0.051
  36. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. J Clin Oncol. 2019 03 20; 37(9):741-750.
    View in: PubMed
    Score: 0.050
  37. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes. Gynecol Oncol. 2016 09; 142(3):548-56.
    View in: PubMed
    Score: 0.042
  38. PI3K/AKT Signaling Regulates H3K4 Methylation in Breast Cancer. Cell Rep. 2016 06 21; 15(12):2692-704.
    View in: PubMed
    Score: 0.042
  39. Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer. Oncotarget. 2016 Mar 15; 7(11):13153-66.
    View in: PubMed
    Score: 0.041
  40. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010 Dec 16; 468(7326):968-72.
    View in: PubMed
    Score: 0.028
  41. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell. 2007 Jun 15; 129(6):1065-79.
    View in: PubMed
    Score: 0.022
  42. A genetic screen for candidate tumor suppressors identifies REST. Cell. 2005 Jun 17; 121(6):837-48.
    View in: PubMed
    Score: 0.019
  43. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res. 2004 Dec 15; 64(24):8867-75.
    View in: PubMed
    Score: 0.019
  44. Simian virus 40 large T antigen targets the spindle assembly checkpoint protein Bub1. Proc Natl Acad Sci U S A. 2004 Jan 27; 101(4):947-52.
    View in: PubMed
    Score: 0.018
  45. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell. 2003 Dec; 4(6):463-76.
    View in: PubMed
    Score: 0.017
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.